🟢 Clearpoint Neuro is trading 5.5% up today after Q3 revenue rose 36% year over year

Clearpoint Neuro is trading at $11.14, up 5.49%, after reporting Q3 revenue of $12.1 million, up 36% year over year.

• Neurosurgery navigation and therapy revenue rose 59%; 2026 revenue expectations are $48–$50 million.
• Shares also rose 8.98% on October 28; Stifel maintained Buy but lowered its target to $18 on October 29.
• Gross margin fell to 58% from 63%, partly due to new laboratory overhead and acquired-asset amortization.